Below find some interesting ovarian cancer research studies I heard at the SGO meeting.
Scientific Plenary II: Building Bridges - Pioneering Protocols and Scientific Progress
Long Term Survival of GOG 252 'Randomized Trial of Intravenous Versus
Intraperitoneal Chemotherapy plus Bevacizumab in Advanced Ovarian
Carcinoma: An NRG Oncology/GOG Study' J. Walker
#SGOmtg. Dr Walker GOG 252 - no gross residual disease population - Can you completely resect? Can you get CA125 to less than 10 in 3 cycles. #gyncsm pic.twitter.com/qMksxlPgFx
— Dee Sparacio (@womenofteal) March 18, 2022
What's Next After Bevaciumab Resistance? Targeting Metabolic Vulnerabilities in Ovarian Cancer – D. Glassman GLSi is a novel therapeutic strategy to treat AVA-resistant ovarian cancer
#SGOmtG Dr Glassman : Bevaczumab resistance in OC
GLS expression GLS inhibitor and hypoxia , #gycsm pic.twitter.com/A7kjIBHIqB
— Dee Sparacio (@womenofteal) March 18, 2022
Final Overall Survival Results from SOLO3: Phase III Trial Assessing Olaparib Monotherapy Versus Non-Platinum Chemotherapy in Heavily Pretreated Patients with Germline BRCA1 and/or BRCA2-Mutated Platinum-Sensitive Relapsed Ovarian Cancer – R. Penson
Investigation of PARP Inhibitor Resistance Through the Analysis of Serially Collected Circulating Tumor DNA (ctDNA) in Ovarian Cancer Patients – Speaker: Y. Kim
#SGOMtg Dr Kim PARP progression and gene mutations #gyncsm pic.twitter.com/8BHkdtz1LK
— Dee Sparacio (@womenofteal) March 18, 2022
Evolution of the Ovarian Cancer Treatment Paradigm, Including Maintenance Treatment, in the US and Europe: A Real-World Chart Review Analysis (2017-2020) – Speaker: K. Moore
Dr Moore global study of use of maintenance therapy #SGOMtg #gyncsm pic.twitter.com/GQXBwelTEz
— Dee Sparacio (@womenofteal) March 18, 2022
Knowledge Measure for Ovarian Cancer Research (KnoMOR): Development and
Psychometric Testing Results of a Patient-Centered Knowledge Measure –
Speaker: L. Meyer
Yes!! Dr. Larissa Meyer: Knowledge is a prerequisite to informed choice. Development of KnoMOR (Knowledge Measurement for Ovarian Cancer Research) Shared decision making tool. #SGOmtg #GYNcsm pic.twitter.com/miuAi5ZGuD
— Annie Ellis (@Stigetta) March 18, 2022
Scientific Plenary II: Building Bridges - Pioneering Protocols and Scientific Progress
Hardest OVARIO trial #SGOmtg heavily pretreated population.
— Dee Sparacio (@womenofteal) March 19, 2022
53% had PFS at 28 months. S not available at this time. #gyncsm pic.twitter.com/wr9Ze4NMOP
Prospective, Randomized Trial of Streamlined Genetic Education and
Testing for Patients with High Grade Epithelial Ovarian, Fallopian and
Peritoneal Cancer – Speaker: R. Previs
Dr. Rebecca Previs presents results of video assisted streamlined genetic education and testing for ovarian cancer #SGOmtg #GYNcsm #PECPatAdv pic.twitter.com/EkzCqvk3qo
— Annie Ellis (@Stigetta) March 19, 2022
Effectiveness of Platinum-Based Chemotherapy after Progression on Poly ADP Ribose Polymerase (PARP) Inhibitor in Epithelial Ovarian Cancer – Speaker: K. Dugan
#SGOmtg Dr Dugan For patients who progress after PARP retreatment with platinum drugs is reasonable #gyncsm pic.twitter.com/AYBB2bjES7
— Dee Sparacio (@womenofteal) March 19, 2022
A Novel Combo of Niraparib and Anlotinib in Platinum-Resistant Ovarian Cancer, the Final Efficacy and Safety Report of ANNIE Study, a Phase II, Multi-Center Trial – Speaker: J. Liu , This is a Niraparib and Anlotinib ( kinase inhibitor) combo used in Platinum-Resistant OC (ANNIE Study) Promising combo With tolerable toxicity . PPMD1 mutation may be what leads to resistance in niraparib.
Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer – D. Richardson
#SGOmtg Ph1 Expansion Study of Upifitamab Rilsodotin (UpRi NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian
— Dee Sparacio (@womenofteal) March 19, 2022
Cancer - Dr Richardson , 97 patients in 2 groups , no severe toxicity, prior lines
ORR 44% in NaPi 2b expression patients #gyncsm pic.twitter.com/c8a3Idtj0A
Clinical Outcomes of Ovarian Cancer Patients Treated with the Novel
Engineered Cytokine Nemvaleukin Alfa in Combination with the PD-1
Inhibitor Pembrolizumab: Recent Data from ARTISTRY-1 – Speaker: I. Winer
#SGOmtg Ovarian Cancer Treated with the Novel Engineered
— Dee Sparacio (@womenofteal) March 19, 2022
Cytokine Nemvaleukin Alfa in Combination with the PD-1 Inhibitor Pembrolizumab ARTISTRY-1 – Dr I. Winer
16 patients treated, 5 had response. Well tolerated. Evidence of tumor response , FDA fast track Designation #gyncsm pic.twitter.com/9tyvTZFOvK
#SGOmtg Dr Matulonis Soraya study : High folate expressing ovarian cancer treated with mirvetuximab MIRV antibody drug conjugate ORR 34%, mDOR 6.9 months 5 complete responses mPFS 5.4 mo
— Dee Sparacio (@womenofteal) March 19, 2022
AE ocular events( blurred vision) were reversible , nausea #gyncsm pic.twitter.com/oNV8XjpoEG
#SGOmtg PRIME study - niraparib as maintenance in newly dx adv OC individual dosing
— Dee Sparacio (@womenofteal) March 20, 2022
PFS 24.8 months with Niraparib vs 8.3 months in placebo
Immature OS . #gyncsm pic.twitter.com/kbAz1QBJzk
#SGOmtg Dr Gershenson presenting on LGSOC using NGS
— Dee Sparacio (@womenofteal) March 20, 2022
Characteristics : Young age, relative chem resistance, responds to endocrine therapy #gyncsm pic.twitter.com/QzYZfJ7SGw
Dr David Gershenson presenting study showing better survival in women with low grade serous ovarian cancer whose tumors have MAPK mutations @RareOvarCancers #sgomtg pic.twitter.com/7c2ydfwwzN
— Karen Lu (@karenluMD) March 20, 2022
Scientific Plenary V: Bullseye! Precision Medicine and Hitting the Right Targets
RNAseq Correlative Biomarkers IFIT1B and VSTM5 Predict Progression Free
Survival and Clinical Benefit in a Multi-Site Phase I/II Trial of
Olaparib and Tremelimumab for gBRCAm Recurrent Ovarian Cancer –
S. Adams
#SGOMtg Dr Adams Olaparib and Tremelimumab ( CTLA4
— Dee Sparacio (@womenofteal) March 20, 2022
In women with OC with BRCA mutations
Combo may be a benefit for a subset of women with OC #gyncsm pic.twitter.com/7rwhexJQ02
#SGOMtg Dr Adams Olaparib and Tremelimumab ( CTLA4
— Dee Sparacio (@womenofteal) March 20, 2022
In women with OC with BRCA mutations
Combo may be a benefit for a subset of women with OC #gyncsm pic.twitter.com/7rwhexJQ02
Turning Cold into Hot: Combination of Pembrolizumab with Bevacizumab and Oral Metronomic Cyclophosphamide Increases Immune Cell Migration into the Tumor Microenvironment in Responding Patients with Recurrent Ovarian Cancer – N. Gaulin
The Role of Mesenchymal Stem Cells in the Ovarian Cancer Precarcinoma Microenvironment – Speaker: T. Orellana
#SGOMtg Role of Mesenchymal Stem Cells in the Ovarian Cancer Precarcinoma Microenvironment – Speaker: T. Orellana#gyncsm pic.twitter.com/pHODjYeAPv
— Dee Sparacio (@womenofteal) March 20, 2022
Defining the Impact of Chromobox 2 on the Immune Tumor Microenvironment
of High Grade Serous Ovarian Carcinoma – L. Brubaker
#SGOMtg Dr Brubaker CBX2 ( epigenetic transcription regulator has high expression in HGSOC , poor survival.
— Dee Sparacio (@womenofteal) March 20, 2022
Mouse study - less tumor when CBX2 knocked down .
CBX2 directly regulates micrenvironment
Working on CBX2 inhibitor . #gyncsm pic.twitter.com/vOkLKxauYx
Stay tuned for a post on Cervical Cancer.
Dee
Every Day is a Blessing!
No comments:
Post a Comment